SCHEMBL7066879

SCHEMBL7066879

CC(C)CC(NS(=O)(=O)c1ccc(C(C)C)cc1)C(=O)O

nearest known ligand 0.69

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 8/20 0.69
MMP9 P14780 7/20 0.69
MMP13 P45452 2/20 0.69
MMP1 P03956 1/20 0.69
MMP3 P08254 1/20 0.69
MMP7 P09237 1/20 0.69
KDM4E B2RXH2 2/20 0.60
MEN1 O00255 1/20 0.55
CYP2C9 P11712 1/20 0.55
KMT2A Q03164 1/20 0.55
ALDH1A1 P00352 1/20 0.54
CYP2C19 P33261 1/20 0.54
MMP8 P22894 2/20 0.49
MMP12 P39900 1/20 0.49
MMP14 P50281 1/20 0.49
CA2 P00918 2/20 0.49
ADAMTS4 O75173 2/20 0.49
CA1 P00915 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7062306 0.88 MMP2 (0.69) MMP2MMP9MMP13MMP1MMP3
SCHEMBL8840147 0.88 MMP2 (0.69) MMP2MMP9MMP13MMP1MMP3
SCHEMBL3969625 0.87 MMP9 (0.71) MMP2MMP9MMP13MMP1MMP3
SCHEMBL11351046 0.87 MMP9 (0.71) MMP2MMP9MMP13MMP1MMP3
SCHEMBL7066619 0.87 MMP9 (0.71) MMP2MMP9MMP13MMP1MMP3
SCHEMBL5191083 0.86 MMP2 (0.70) MMP2MMP9MMP13MMP1MMP3
SCHEMBL6561338 0.86 MMP2 (0.70) MMP2MMP9MMP13MMP1MMP3
SCHEMBL15251807 0.86 MMP2 (0.70) MMP2MMP9MMP13MMP1MMP3
SCHEMBL15251876 0.85 MMP2 (0.92) MMP2MMP9MMP13MMP1MMP3
SCHEMBL7062885 0.85 MMP2 (0.69) MMP2MMP9MMP13MMP1MMP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030130251-A1 Amino lactam sulfonamides as inhibitors of A-beta protein production THOMPSON LORIN A (US) 2003-07-10 US claimed
US-6503901-B1 Alzheimer*s disease and Down*s syndrome treatment BRISTOL MYERS SQUIBB PHARMA COMPANY 2003-01-07 US claimed
US-20030130251-A1 Amino lactam sulfonamides as inhibitors of A-beta protein production THOMPSON LORIN A (US) 2003-07-10 US disclosed
US-6503901-B1 Alzheimer*s disease and Down*s syndrome treatment BRISTOL MYERS SQUIBB PHARMA COMPANY 2003-01-07 US disclosed
EP-1222176-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION Bristol-Myers Squibb Pharma Company (US) 2002-07-17 EP disclosed
EP-1218377-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION Bristol-Myers Squibb Pharma Company (US) 2002-07-03 EP disclosed
WO-2001027108-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) 2001-04-19 WO disclosed
WO-2001027091-A1 AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION DU PONT PHARMACEUTICALS COMPANY (US) 2001-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130251-A1 Amino lactam sulfonamides as inhibitors of A-beta protein production APP, APH1A, BACE1 MMP2 1807/4885MMP9 1513/4885MMP13 3485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.